AUTHOR INDEX

Aarbakke, J. 217

Brück, K. 163

D'Incalci, M. 291

Farmer, P. B. 301
Farrell, G. C. 375
File, S. E. 265

Goldman, I. D. 27

Johnston, B. B. 359

Marion, P. L. 1
Matherly, L. H. 27
Miller, R. H. 1

Pellow, S. 265
Powis, G. 57

Robinson, W. S. 1

Seither, R. L. 27
Slørdal, L. 217

Wise, R. A. 227

Zeisberger, E. 163

SUBJECT INDEX

Aclacinomycin A
  bis(substituted aminoalkylamino)anthraquinones 107, 108
  metabolism 90
    scheme 73
Actinomycin D
  metabolism 133, 134
  structure 132, 133
Adverse drug reactions
  alkylating agents 305, 309, 310, 317, 318, 324, 325
  anthracyclines 99–102
Alkylating agents *see also* individual classes and compounds
  metabolism 301–42
Aniline mustard metabolism 327, 328
Animal models, hepatic drug metabolism 375–77
Anthracyclines 65–102
  aglycone metabolites 72
  alkylation 81–84
  antitumor activity 95–98
  cardiotoxicity 99–102
    protection 101
  cleavage reactions 70–72
  clinical activity 68, 69
  electron spin resonance 75
  free radical formation 74–78
  history 65
  keto reduction 69, 70
  metabolism 69–75
    drug effects 94, 95
    in vitro 69–84
    in vivo 84–95
  metal complexes 78–81
  NADPH-cytochrome P-450 reductase 70
  oxygen radical formation 78–81
  pharmacokinetic properties 83
  reactive species formation 82
  skin toxicity 102
  structure–activity relationships 67, 68
  structures 66, 67
  tumor cell metabolism 93, 94
Antifolates
  effects and leucovorin 39, 40
  hydroxylation 45, 46
  metabolism 27, 45
  polyglutamylation 30–32, 36–38
    modulation and cells 34–36
Anxiolytic compounds, novel 265
Aziridinylbenzoquinones 119–28, 333, 334
  alkylation mechanisms 122
  antitumor activity 126–28
  chemical reactivity 121
  degradation mechanisms 122
  free radical formation 123, 124
  metabolism 123–28
  metabolites 124, 125
  structure–activity relationships 121
  structure 120
  transport 333
Aziridinyl compounds
  metabolism 329–33
  pharmacokinetics 331
  toxicity 332
Azo-mustards, metabolism 326, 327
AZQ metabolism 334, 335

Benzodiazepines
  aggressive behavior 270–72
  anxiolytic action 266, 267
  convulsions 269, 270
  dependence 277–79
  developing rat 281–83
  discernable stimuli 266
  exploration 272–74
  food and water intake 276, 277
  learning 274–76
  memory 274–76
  rewarding properties 279, 280
  stress effects 268
  withdrawal 278
Bis(substituted aminoalkylamino)anthraquinones 102–108
  cardiotoxicity 107, 108
  clinical activity 103, 104
  free radical formation 104, 105
  metabolism 104–108
  pharmacokinetics 106, 107
  side-chain metabolism 105
  structure–activity relationships 102, 107
  structures 103
Busulphan 321–24
  metabolism 323
  toxicity 324

Cardiac disorders and drug metabolism 394
Chlorambucil 305–10
  metabolism 307, 308
  pharmacokinetics 308, 309
  structure 305
  toxicity 309, 310
  transport 307
  uptake 306
Corticosteroids and thermal adaptation 180
Cyclophosphamide, anticancer drug effects 217–19

Daunorubicin
  formation mechanism 82
  in vivo metabolism 84–86
4-Demethoxydaunorubicin, *in vivo* metabolism 88
Diabetes mellitus, drug metabolism 383–86
  alterations 385, 386
  mediators 385
Diaminoantifolates
  7-hydroxyl derivatives 45–49
  metabolism 27–50

polyglutamylation 42, 43
Dihydrofolate reductase 29,30
Doxorubicin
free radicals 74–78
in vivo metabolism 86, 87
redox cycling 78
Drug craving, reward pathways 248–50
Drug dependence
benzodiazepines 277–9
brain-stimulated reward 237
anatomy 238
drug abuse interaction 239–41
pharmacology 237, 238
concentration gradients 242, 243
food reward 241
frontal cortex 245, 246
negative reinforcement 230–36
opiate deficiency 236
stress 234, 235
nucleus accumbens 244, 245
physical, opiate 231, 232
depressants 233, 234
positive reinforcement 236, 248
psychomotor stimulant 246–48
reward pathways 277–51
ventral tegmental area 243, 244
Drug metabolism
acid–base disturbances 396
anticancer drug effects 217–23
blood–gas abnormalities 392
cardiopulmonary dysfunction 393–95
concomitant drug treatment 222, 223
diabetes mellitus 383–86
hepatic 375–77
immunization 380
interferon effects 380, 381
malignancy 386–88
mediators of altered 376
pyrogen-induced fever 377–79
renal disease 381–83
respiratory disease 395, 396
thyroid disease 389–93
viral infection 379
Drug misuse
benzodiazepines 370
clonidine 369
etiology 360
model
medical 362
moral 361, 362
social learning 362
non-pharmacological treatment 370–72
prevention 372
treatment 359–72
Drug reward 229, 230
and dependence 227–51

Epidoxorubicin, *in vivo* metabolism 87, 88
Estramustine phosphate
metabolism 321
structure 320

Fever and drug metabolism 377–79
Folate
metabolism 27–45
natural, conversions 27, 28
Folyl polyglutamate synthetase, drug target 43–45
Free radical formation, anthracyclines 74

Hepatocellular carcinoma, hepadna virus role 16–21
Hexitol derivatives, metabolism 335–37
7-Hydroxymethotrexate
cytotoxicity 48, 49
modulating role 46, 48

Lapachols 130–32
metabolism 131, 132
structure 131

Melphalan
analysis methods 313
drug interactions 318, 319
metabolism 315, 316
pharmacokinetics 316, 317
resistance 319, 320
structure 311
toxicity 317, 318
transport 314, 315
Menogaril metabolism 90
Metabolic rate and sweat rate 172, 173
Methadone
opiate abuse 365–68
pregnancy 369
withdrawal management 368, 369
Methotrexate
drug metabolism 220
polyglutamylation 34, 38
Methotrexate polyglutamates
folate enzymes 39–41
leucovorin rescue 38, 39
selectivity 41, 42
properties 32–34
Mitomycins 108–19
antitumor activity 117–19
biological activation pathway 113
electron spin resonance 115
metabolism 109–19
mitosene formation 114
pharmacokinetics 116
products formed 112
structure–activity relationships 108, 109
structures 109
Mitomycin C
DNA interaction 339, 340
metabolism 337–39
pharmacokinetics 340–341
structure 337
Mitosene 114
Monoamines and thermoregulation 185–205

Nitrogen mustard 301
alkylation mechanisms 302
distribution 304
toxicity 305
transport 303, 304

Opiate abuse 364–68
methadone 365–68
Opioid peptides 228
drug misuse 363, 364
endogenous deficiency 236
reinforcing effects 229
reward substrate 243–46

Prednimustine metabolism 310, 311
Procarbazine and drug metabolism 219, 220

Quinoid anticancer agents 57–137 *see also* individual classes and compounds
antitumor activity 64
bioreductive alkylation 64, 65
chemical reactions 58
cytotoxicity 61–63
mechanisms 136
metabolism 59–63
natural 57
oxygen radical formation 60, 61

Radiosensitizers and drug metabolism 222
Renal disease and drug metabolism 381–83
Reward, minor tranquilizers 279, 280
Reward pathway
drug craving 248–50
drug dependence 227–48

Spirohydantoin mustard metabolism 328, 329
Streptonigrins 128–30
metabolism 129, 130
structure 128, 129

Teroxirone
metabolism 341, 342
structure 341
Thermogenesis
non-shivering 167–69
shivering 169, 170
Thermoregulation
adaptive changes 163–206
amine role 204
cold adaptation 173–75
process 199
cold defence modification 166–72
cold-induced responses 167–70
connectivity diagram 182
effector system, modification 164–72
heat adaptation 175
heat dissipation modifications 164, 165
heat tolerance 177
6-hydroxydopamine lesions 194, 195
5-hydroxytryptamine system 201–203
lesion studies, guinea pig 193–95
long-term modifications 164
monoamines 185–205
brain slice 190, 191
electrophysiological single unit 188–90
microinjections 186–88
neuronal model 191–93
neuroanatomy 199
neurochemistry 200, 201
noradrenaline excretion and adaptation 198
noradrenergic systems 195–99
descending and ascending 202, 203
resting metabolic rate 166, 167
shivering thresholds and noradrenaline 196, 197
short-term adaptation 177–79
threshold deviations 176, 177
neuronal model 181–85
Thiotepa and drug metabolism 219
Thyroid disorders and drug metabolism 389–93
Thyroid hormones and thermal adaptation 179, 180
Tissue insulation, cold responses 170–72
Tolerance, minor tranquilizers 280, 281
Treosulphan 324
toxicity 325
Triazine anticancer agents
drug interactions 297
metabolic pathways 292, 293
extrahepatic 293, 294
hepatic 292, 293
man 295–97
species 294, 295
species differences 294, 295
structures 291

Virus, hepadna
antigenic structure 2, 3
codon preferences 9, 10
genome structure 4–7
and hepatocellular carcinoma 16–21
state 18–21
morphology 2
polypeptides 3, 4
replication mechanism 10–14
scheme 12
retrovirus homology 7–9
retrovirus relationship 14–16